ArticleProbiotics and antimicrobial proteins2026
Uric Acid-Degrading Lacticaseibacillus paracasei CPU202306 Ameliorates Hyperuricemia by Regulating Uric Acid Metabolism and Intestinal Microecology in Mice.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Oral supplementation ofApplied and environmental microbiology · 2026Article
- Biological Characteristics of a ProbioticFoods (Basel, Switzerland) · 2026Article
- Complex interactions of gut-derived short-chain fatty acids in hyperuricemia and gout pathophysiology.Frontiers in microbiology · 2026Review
- Research progress on the correlation between gut microbiota and the occurrence of hyperuricemia.Frontiers in microbiology · 2026Review
- Article
- One mechanism of Sishen Pill on diarrhea with kidney Yang deficiency syndrome: influencing metabolic function by intestinal microorganisms and enzyme activity mediates the gut-kidney axis.Frontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Hyperuricemia, characterized by elevated levels of uric acid in the blood, poses a significant health threat due to its association with various adverse health outcomes, and lactic acid bacteria from the gut microbiota may offer solutions. Our investigation focused on Lacticaseibacillus paracasei CPU202306, isolated from fermented pickles for its potent uric acid degradation and probiotic properties. This bacterium effectively reduced blood uric acid levels by breaking down uric acid and inhibiting hepatic xanthine oxidase (XOD) and adenosine deaminase (ADA) enzymes. Additionally, it stimulated the production of short-chain fatty acid (SCFAs) in the colon, enhancing the expression of uric acid secretion transport proteins (ATP-binding cassette sub-family G member 2 and organic anion transporter 3) while suppressing absorption transport proteins (glucose transporter 9 and uric acid transporter 1). This orchestrated process promoted uric acid excretion. L. paracasei CPU202306 also improved gut microbiota health by reinforcing tight junction proteins, shifting the microbiota to a healthier composition, and reducing harmful bacteria. This transformation inhibited kidney TLR4/MyD88/NF-κB inflammatory signaling, leading to a significant decrease in pro-inflammatory cytokines and an increase in anti-inflammatory cytokines, mitigating kidney inflammation. Furthermore, the bacterium supported kidney health by influencing amino acid metabolic pathways linked to the gut-kidney axis. In summary, our study highlights the diverse mechanisms through which L. paracasei CPU202306 addresses hyperuricemia, showcasing its therapeutic potential for this condition.
Indexed as
Identifiers
40205164What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.